Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering

REDWOOD CITY, Calif., April 14 Codexis, Inc. announcedtoday that it has filed a registration statement on Form S-1 with the U.S.Securities and Exchange Commission ("SEC") relating to the proposed initialpublic offering of shares of its common stock. Copies of the Codexisregistration statement on Form S-1 can be accessed through the SEC's websiteat edgar.sec.gov. The number of shares being offered and the price range forthe offering have not yet been determined. The shares of common stock to besold in this offering are proposed to be sold by Codexis, Inc.

Credit Suisse Securities (USA) LLC and Goldman, Sachs & Co. will be actingas joint book-running managers, with Piper Jaffray & Co., RBC Capital MarketsCorporation and Thomas Weisel Partners LLC acting as co-managers for theoffering. This offering will be made only by means of a prospectus. Copiesof the preliminary prospectus for this offering may be obtained, whenavailable, from the prospectus department of Credit Suisse Securities (USA)LLC, Attention: Prospectus Department, One Madison Avenue, New York, New York10010, via telephone at 800-221-1037; or from the prospectus department ofGoldman, Sachs & Co., Attention: Prospectus Department, 85 Broad Street, NewYork, New York 10004, via fax at 212-902-9316.

A registration statement relating to these securities has been filed withthe SEC but has not yet become effective. These securities may not be sold,nor may offers to buy be accepted, prior to the time the registrationstatement becomes effective. This press release shall neither constitute anoffer to sell nor a solicitation of an offer to buy nor shall there be anysale of these securities in any state in which such offer, solicitation orsale would be unlawful prior to registration or qualification under thesecurities laws of any such state.

About Codexis

Codexis is a leading developer of proprietary biocatalysts that thecompany believes have the potential to revolutionize chemistry-basedmanufacturing processes across a variety of industries. The company has usedits technology platform to enable biocatalyst-based commercial-scale drugmanufacturing processes and delivered biocatalysts and drug products to someof the world's leading pharmaceutical companies. Codexis has a fundedcollaboration in the biofuels market, and the company is pursuing fundedcollaborations in several other bioindustrial markets, including carbonmanagement, water treatment and chemicals.

Contact: Lyn Christenson, [email protected], 650-421-8144 orJustin Jackson, Burns McClellan, [email protected], 212-213-0006.

SOURCE Codexis, Inc.

Latest Press Release on General News

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...

Dr. Andres Bustillo Responds to Miami's Growing Interest in Facelift Procedures

In response to the growing demand for facelifts in Miami , Dr. Andres Bustillo , a renowned board-certified facial plastic surgeon, is offering advanced and time-proven techniques in f...

Deepening the Partnership: Dawn Health Introduces Ekiva for Enhanced Disease Management of Paroxysmal Nocturnal Hemoglobinuria (PNH)

COPENHAGEN, Denmark , April 8, 2024 /PRNewswire/ -- Building upon their partnership announced last year, digital health leader Dawn Health and global pharmaceutical company Nov...